After Spinning Onyx into Gold, Coles Returns to Lead a CNS Startup

December 15, 2014 3:05 PM

3 0

Tony Coles could easily be on a beach sipping mai tais right now. You can plan for an early retirement in biotech when you turn two different companies around and steer the latest one of them into a $10 billion buyout.

But the 54-year-old Coles, who helped restructure NPS Pharmaceuticals and then lead Onyx Pharmaceuticals to a sale to Amgen last year, is showing that he has no plans to kick back and call it a career. He’s come out of a year-plus hiatus today to announce his latest move—and it’s not the sort that y...

Read more

To category page